<DOC>
	<DOCNO>NCT02475304</DOCNO>
	<brief_summary>The purpose study investigate , whether FP187 effective treatment mild moderate psoriatic arthritis .</brief_summary>
	<brief_title>Proof-of-concept Study Forward Pharma ( FP ) 187 Patients With Mild/Moderate Psoriatic Arthritis</brief_title>
	<detailed_description>The study randomise , double blind , placebo-controlled proof-of-concept trial investigate efficacy safety FP187 compare placebo 24 week treatment patient mild moderate psoriatic arthritis ( PsA ) . The daily dose level FP187 arm 500 mg. After completion double blind treatment 24 week , patient irrespective treatment arm switch additional 24 week open-label treatment phase 500 mg / day FP187 . Patient complete 24 week double blind part study schedule eligible participation open-label part .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Psoriatic</mesh_term>
	<mesh_term>Dimethyl Fumarate</mesh_term>
	<criteria>document clinical diagnosis mild moderate psoriatic arthritis least 3 month active psoriatic arthritis least 2 tender 2 swollen joint sign informed consent willingness ability comply study procedure besides psoriatic arthritis , patient must good general health opinion investigator , determine medical history , physical examination , vital sign , electrocardiography clinical laboratory parameter patient use methotrexate , stable dosis 20mg per week least 90 day prior study entrance present serious toxic side effect attributable methotrexate female childbearing age must either surgically sterile use highly effective medically accept contraceptive method female patient pregnant breastfeed plan become pregnant entire trial period male patient plan pregnancy partner entire trial period , practice unprotected sexual relationship entire trial period know allergy constituent product test known immunosuppressive disease ( e.g . HIV , AIDS ) know history latent active granulomatous infection include tuberculosis , histoplasmosis coccidioidomycosis presence another inflammatory disease include limited rheumatoid arthritis , ankylose spondylitis , systemic lupus erythematous Lyme disease presence chronic widespread pain syndrome patient pustular form psoriasis , erythrodermic guttate psoriasis patient another nonpsoriatic arthropathy ( e.g . osteoarthritis ) presence another serious progressive disease include skin malignancy presence history malignancy ( except basal cell carcinoma , squamous cell carcinoma situ skin treat evidence recurrence within 5 year , cervix cancer situ treat evidence recurrence . ) use time biological Disease Modifying Antirheumatic Drug ( bDMARD ) etanercept , adalimumab , golimumab , certolizumab pegol infliximab corticosteroid injection within 12 week use dimethyl fumarate ( DMF ) contain product within 12 week use retinoid treatment , immunosuppressive treatment , cytostatics drug know harmful effect kidney within last 3 month use cyclosporine , corticosteroid psoralen + UVA ( PUVA ) treatment within 4 week ongoing stomach intestinal problem ( e.g . gastritis peptic ulcer ) Aspartate transaminase ( AST ) Alanine transaminase ( ALT ) &gt; 2x upper normal normal limit ( UNL ) Gamma Glutamyl Transferase ( gammaGT ) result &gt; 2.5 UNL estimate creatinine clearance ( CockcroftGault ) &lt; 60ml/min leucopenia ( leucocyte count &lt; 3.5/nl ) , eosinophilia ( &gt; 750 / micro l ) lymphocytopenia ( &lt; 1.02 / nl ) protein detect urine stick test participation another clinical trial last 2 month participation trial another psoriatic arthritis treatment within 6 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>